Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actavis
Actavis Acquires Kadian; Extends Specialty Drug Portfolio in U.S.
January 18th, 2009
Actavis announced that it has acquired the brand name drug Kadian® from King Pharmaceuticals for not more than USD127.5M, based on quarterly sales related milestones, ending 30 June 2010. Kadian® which is an extended release morphine sulfate product, is the first originator brand product to be marketed by Actavis US. The company anticipates marketing Kadian® only in the United States. “The acquisition of Kadian is the latest step in Actavis’ strategy to expand our specialty drug portfolio and is well aligned with our emphasis on bringing complex controlled-release products to the marketplace,” said Actavis US CEO Doug Boothe. “Kadian has enjoyed...
Source: Pharma Investments, Ventures & Law Weekly (2009-01-18)
|
